Search
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … Nogapendekin alfa is a human IL-15N72D variant.
Synonyms: Il-15n72d:il-15rec-su/fc soluble complex i, Human interleukin 15 (72-aspartic acid) (human il-15 n72>d isoform)Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalby the presence of ANCAs in the serum. … [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesObeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalThe NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636] … hepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation.
Synonyms: 6-ECDCA, 6-Ethyl-CDCACategories: Farnesoid X Receptor Agonist, Farnesoid X Receptor AgonistsAGRO100
go.drugbank.com/drugs/DB04998InvestigationalAGRO100 is an oligonucleotide that functions as an aptamer and binds to nucleolin, a protein found intranuclear in all cells, but uniquely expressed on the surface of tumor cells. … Such binding leads to internalization of the complex, and a strong anti-proliferative response in the tumor cell.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. … Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States.
Mixtures: PRAVAFEN® CAPSULASCategories: P-glycoprotein substratesDabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: PRADAXA® 150 MG, DABITROM® 150Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsOxazepam
go.drugbank.com/drugs/DB00842ApprovedOxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.
Categories: Heterocyclic Compounds, 2-RingDequalinium
go.drugbank.com/drugs/DB04209Approved[A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] It is also used in vaginal tablets to treat bacterial vaginosis.[L42190]
Synonyms: 1,1'-(1,10-Decanediyl)bis(4-amino-2-methylquinolinium) dichloride, Decamethylenebis(4-aminoquinaldinium chloride)Mixtures: EFISOL-C, JASIMENTH C PASTILLESAutophagy
smpdb.ca/view/SMP0578913Signalingthe fasted state), calcium/calmodulin‑dependent protein kinase kinase 2 (CAMKK2) directly phosphorylates and activates AMPK, which in turn phosphorylates ULK1 to trigger phagophore formation in an mTOR‑independent … An increased AMP:ATP ratio activates AMPK and concurrently inhibits mTORC1, resulting in dephosphorylation and activation of ULK1 kinase activity to nucleate the phagophore.
Enzymes: Activating molecule in BECN1-regulated autophagy protein 1